Experimental combo for tough blood cancers hits early snag
NCT ID NCT04702425
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a combination of two experimental drugs, VOB560 and MIK665, in 37 people with relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma. The drugs aim to block proteins that help cancer cells survive, forcing them to die. The study was terminated early, so results on safety and effectiveness are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VOB560 and MIK665 (two experimental drugs that block proteins protecting cancer cells)
What this could lead to
If it works, this combination could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong
This was a very early (phase 1) trial that was terminated, so we don't know if the combination is safe or effective. The drugs may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ghent, 9000, Belgium
-
Novartis Investigative Site
HUS, FIN-00029, Finland
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Sunto Gun, Shizuoka, 411 8777, Japan
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Uni of TX MD Anderson Cancer Cntr UT MD Anderson Cancer Ctr
Houston, Texas, 77030, United States